Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”
Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic […]
